FOUNTAIN HILLS, Ariz., Sept. 23 /PRNewswire/ -- Sunridge International (OTC Bulletin Board: SNDZ) announced today that it has shipped its first order to Ameco Medical Equipment L.L.C., its exclusive distributor for several Middle Eastern countries. AME plans to start its marketing rollout of Pneumatic Trabeculoplasty (PNT) throughout the region, while simultaneously conducting a short study to gain reimbursement approval for the PNT procedure. Once established, the population of glaucoma sufferers waiting for treatment can be helped.
Sunridge International's CEO, G. Richard Smith states, "This is an important step for our company. Our focus this year has been expanding our distribution network worldwide, and entering the Middle Eastern market, with the high incidence of glaucoma in its population, can and should produce millions in revenue for our company."
Glaucoma is the second leading cause of blindness, affecting over 70 million people worldwide. PNT has been proven (through studies completed over the last 10 yrs) to be a safe, effective, non-invasive and a cost effective alternative for treatment for glaucoma and ocular hypertension. The 2-minute treatment has been developed, patented, and distributed by Sunridge International, wholly owned subsidiary, Ophthalmic International (www.oi-pnt.com).
For full details of PNT and its application, we invite you to visit Sunridge International's website at www.sunridgeint.com.
Forward-looking statements in this release are made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements involve risks and uncertainties, including without limitation, continued acceptance of the company's products, increased lev